Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma

Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma

Several lines of evidence support immunotherapy in hepatocellular carcinoma (HCC). We have shown that intratumoral injections of the immune primer ilixadencel (pro-inflammatory allogeneic dendritic cells) are safe in renal-cell carcinoma. Here, we assessed ilixadencel as a single agent and combined...

Full description

Bibliographic Details
Main Authors: Magnus Rizell, Malin Sternby Eilard, Mats Andersson, Bengt Andersson, Alex Karlsson-Parra, Peter Suenaert
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-01-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
cell therapy
immunotherapy
allogeneic
dendritic cells
ilixadencel
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00019/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00019/full

Similar Items